Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort

Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a first-line treatment for advanced ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Conic, Irena, Nedovic, Bojan, Stojnev, Slavica, Todorovska, Ilinka, Dimitrijevic, Aleksandra, Krstic, Miljan, Djordjevic, Ivana, Djordjevic, Biljana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144683/
https://www.ncbi.nlm.nih.gov/pubmed/35630024
http://dx.doi.org/10.3390/medicina58050607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144683/
https://www.ncbi.nlm.nih.gov/pubmed/35630024
http://dx.doi.org/10.3390/medicina58050607

Ejemplares similares